Table 3

Objective markers of bronchial inflammation and systemic allergy after 1 year of treatment

ActivePlaceboDifference (95% CI)p Value
∆FENO−4.88 (−9.3 to −0.4)2.82 (−3.5 to 9.2)−7.13 (−13.6 to −0.7)0.03
∆FENO (high baseline FENO)*−27.30 (−37.6 to −17.0)−2.53 (−24.0 to 18.9)−29.70 (−47.2 to −12.2)0.001
∆ Eosinophil count (%)−0.06 (−0.15 to 0.03)−0.02 (−0.12 to 0.07)−0.04 (−0.20 to 0.08)0.42
∆ FEV1 (% predicted)−0.1 (−1.6 to 1.4)1.4 (−0.9 to 3.6)−2.1 (−4.6 to 0.5)0.11
∆ PEF (% predicted)2.6 (0.5 to 4.6)5.1 (2.1 to 8.1)−2.2 (−5.6 to 1.2)0.20
∆ FEF50 (% predicted)−4.7 (−8.8 to −0.5)−5.2 (−11.6 to 1.2)−2.0 (−8.4 to 4.5)0.55
Total IgE4.6 (−3.5 to 12.6)3.7 (−4.1 to 11.5)2.9 (−9.9 to 15.7)0.66
∆ Cat-specific IgE8.2 (−0.4 to 16.7)35.4 (17.8 to 53.0)−26.0 (−44.1 to −7.9)0.005
∆ Dog-specific IgE−1.9 (−10.4 to 6.5)13.9 (−10.0 to 38.2)−14.6 (−36.5 to 7.3)0.19
∆ Dust mite specific IgE
 Der. farinae3.5 (−6.2 to 13.2)13.6 (−0.7 to 27.9)−8.2 (−25.9 to 9.5)0.36
 Der. pteronyssinus−2.6 (−9.7 to −4.5)7.2 (−5.4 to 19.8)−6.4 (−20.1 to 7.3)0.36
  • All data were calculated using last observation carried forward to impute missing values. Data are expressed as mean (95% CI) absolute changes in FENO (ppb), eosinophil count (as % of total white cell count) and lung function variables (as % predicted value), and mean (95% CI) percentage change in total or specific IgE levels (kU/litre) relative to baseline level over the 1-year study period.

  • * Analysis of change in FENO in the subgroup of patients with abnormally raised FENO (>45 ppb) at baseline. In this group the mean (SD) baseline FENO in ppb was active 81.8 (44.2; n=56) and placebo 80.8 (32.3; n=23). For specific and total IgE and eosinophil counts, n=175 active, 91 placebo; for all other analyses, n=189 active, 93 placebo.

  • Der. farinae, Dermatophagoides farina; Der. pteronyssinus, Dermatophagoides pteronyssinus; FEF50, forced expiratory flow at 50% of vital capacity; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow.